Trials / Conditions / NAFLD (Nonalcoholic Fatty Liver Disease)

NAFLD (Nonalcoholic Fatty Liver Disease)

24 registered clinical trials studyying NAFLD (Nonalcoholic Fatty Liver Disease) — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Accurate Point of Care Liver Disease Diagnostics (Phase 2) NCT07518784	University of California, San Diego	—
Not Yet Recruiting	Chrononutrition/ Chronotoxicity Intervention in People With Metabolic-associated Steatotic Liver Disease. NCT06705868	Cyprus University of Technology	N/A
Withdrawn	Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy NCT07255781	University of California, San Diego	—
Not Yet Recruiting	Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients NCT07168551	Assiut University	—
Recruiting	The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health NCT07093346	University of Nottingham	N/A
Not Yet Recruiting	Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions NCT06932289	VA Greater Los Angeles Healthcare System	N/A
Not Yet Recruiting	Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease NCT06739486	Assiut University	—
Active Not Recruiting	Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET NCT07366710	Rigshospitalet, Denmark	N/A
Recruiting	Digital Early Warning System for Acute Lung Injury in Liver Surgery NCT07070362	Beijing Tsinghua Chang Gung Hospital	—
Not Yet Recruiting	Studying Non Alcoholic Fatty Liver Disease and Liver Fibrosis Among Systemic Lupus Erythematosus Patients at A NCT06601361	Assiut University	—
Completed	Raspberry Ketone Intake Upregulates Circulating FGF21 and Induces Energy Expenditure in Humans NCT06681597	Nanchang University	EARLY_Phase 1
Completed	A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes. NCT07363707	Beni-Suef University	Phase 4
Completed	PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease NCT07146815	Ziekenhuis Oost-Limburg	N/A
Recruiting	Kuwait Adult Diabetes Epidemiological Multidisciplinary (KADEM) Program NCT06115876	Dasman Diabetes Institute	—
Unknown	Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records. NCT05218538	HaEmek Medical Center, Israel	—
Withdrawn	Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism NCT04395950	Columbia University	Phase 1
Completed	A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects NCT04480710	Hepion Pharmaceuticals, Inc.	Phase 2
Withdrawn	Curcumin for Pediatric Nonalcoholic Fatty Liver Disease NCT04109742	Columbia University	Phase 2
Active Not Recruiting	Tocotrienol Against the Progression of End Stage Liver Disease NCT02581085	Chandan Sen	Phase 2
Recruiting	PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies NCT04371042	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	—
Completed	Effects of Exercise on VLDL-TG Metabolism NCT03678727	University of Aarhus	—
Terminated	Losartan for the Treatment of Pediatric NAFLD NCT03467217	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
Completed	Hepatic and Cardiac Metabolic Flexibility in Obese With NAFLD. NCT03583437	University of Aarhus	N/A